Unmasking the complexities of mucinous ovarian carcinoma

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 491-496

  Frumovitz, Michael ^a   Schmeler, Kathleen M ^a   Malpica, Anais ^a   Sood, Anil K ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoma; Mucinous; Neoplasm; Ovary; Tumor

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; K RAS PROTEIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53; TAXANE DERIVATIVE;

CANCER GROWTH; CLINICAL TRIAL; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; METASTASIS POTENTIAL; MUCINOUS CARCINOMA; OVARY CANCER; OVARY CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 77951938633     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.010     Document Type: Review

References (42)

1. Gilks C.B. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23 (2004) 200-205
2. Hess V., A'Hern R., Nasiri N., King D.M., Blake P.R., Barton D.P., et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22 (2004) 1040-1044
3. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
4. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
5. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18 (2000) 106-115
6. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27 (2009) 1419-1425
7. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., and Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23 (2004) 41-44
8. Shimada M., Kigawa J., Ohishi Y., Yasuda M., Suzuki M., Hiura M., et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113 (2009) 331-334
9. Lee K.R., and Scully R.E. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 24 (2000) 1447-1464
10. Riopel M.A., Ronnett B.M., and Kurman R.J. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23 (1999) 617-635
11. Rodriguez I.M., and Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26 (2002) 139-152
12. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
13. Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R., Lin O., Soslow R., et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90 (2003) 378-381
14. Mok S.C., Bell D.A., Knapp R.C., Fishbaugh P.M., Welch W.R., Muto M.G., et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53 (1993) 1489-1492
15. Tonin P.N., Maugard C.M., Perret C., Mes-Masson A.M., and Provencher D.M. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer 6 (2007) 491-497
16. Evans D.G., Young K., Bulman M., Shenton A., Wallace A., and Lalloo F. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet 73 (2008) 338-345
17. Schuijer M., and Berns E.M. TP53 and ovarian cancer. Hum Mutat 21 (2003) 285-291
18. Marchini S., Mariani P., Chiorino G., Marrazzo E., Bonomi R., Fruscio R., et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 14 (2008) 7850-7860
19. Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M., Scurry J.P., Scolyer R.A., Smith A.N., et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94 (2006) 904-913
20. Sarrio D., Moreno-Bueno G., Sanchez-Estevez C., Banon-Rodriguez I., Hernandez-Cortes G., Hardisson D., et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 37 (2006) 1042-1049
21. Brun J.L., Cortez A., Commo F., Uzan S., Rouzier R., and Darai E. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 33 (2008) 1239-1246
22. Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5 (2008) e232
23. Tholander B., Taube A., Lindgren A., Sjoberg O., Stendahl U., and Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 39 (1990) 26-33
24. Tuxen M.K., Soletormos G., and Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21 (1995) 215-245
25. Nolen B., Marrangoni A., Velikokhatnaya L., Prosser D., Winans M., Gorelik E., et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol 112 (2009) 47-54
26. Cho Y.H., Kim D.Y., Kim J.H., Kim Y.M., Kim K.R., Kim Y.T., et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?. Gynecol Oncol 103 (2006) 878-882
27. Leblanc E., Querleu D., Narducci F., Occelli B., Papageorgiou T., and Sonoda Y. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 94 (2004) 624-629
28. Ji J., Forsti A., Sundquist J., Lenner P., and Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol 47 (2008) 1133-1139
29. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 (2007) 3621-3627
30. Pectasides D., Fountzilas G., Aravantinos G., Kalofonos H.P., Efstathiou E., Salamalekis E., et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 97 (2005) 436-441
31. Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Cormio G., et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer 8 (2008) 252
32. Seidman J.D., Kurman R.J., and Ronnett B.M. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27 (2003) 985-993
33. Khunamornpong S., Suprasert P., Pojchamarnwiputh S., Na Chiangmai W., Settakorn J., and Siriaunkgul S. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol 101 (2006) 152-157
34. Stewart C.J., Brennan B.A., Hammond I.G., Leung Y.C., and McCartney A.J. Accuracy of frozen section in distinguishing primary ovarian neoplasia from tumors metastatic to the ovary. Int J Gynecol Pathol 24 (2005) 356-362
35. Yemelyanova A.V., Vang R., Judson K., Wu L.S., and Ronnett B.M. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32 (2008) 128-138
36. Lewis M.R., Deavers M.T., Silva E.G., and Malpica A. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol 30 (2006) 177-184
37. Hart W.R. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24 (2005) 4-25
38. Lee K.R., and Young R.H. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27 (2003) 281-292
39. Ronnett B.M., Yemelyanova A.V., Vang R., Gilks C.B., Miller D., Gravitt P.E., et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32 (2008) 1835-1853
40. Cao D., Ji H., and Ronnett B.M. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 24 (2005) 67-72
41. Oien K.A. Pathologic evaluation of unknown primary cancer. Semin Oncol 36 (2009) 8-37
42. Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S., et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 100 (2009) 546-551